AFFILIATIONS
1 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 Children's Hospital Colorado, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
9 Children's Hospital Colorado, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
10 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
11 Children's Hospital Colorado, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
12 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, University to University of Colorado Anschutz Medical, Aurora, Colorado, United States
ABSTRACT
Lineage switching (LS) has emerged as a serious clinical problem in KMT2A-rearranged (KMT2A-r) B-ALL, particularly following lineage-directed therapies such as CD19 CAR T cells and bispecific T-cell engagers (PMID: 40193715). B-ALL-to-AML conversion is the most frequently observed form of LS in pediatric KMT2A-r leukemia cases and is associated with dismal clinical outcomes. Patients who developed LS following CD19 CAR T-cell therapy had a median survival of only 3.7 months from LS, with no long-term survivors (PMID: 35482927), contrasting with 62.6% 5-year OS in de novo pediatric KMT2A-r AML (PMID: 38621200). However, the mechanisms underlying LS remain poorly understood, in part because of the lack of syngeneic models that faithfully recapitulate pediatric KMT2A-r B-ALL. Existing genetically tractable murine systems have not filled this gap, as retroviral expression of KMT2A-r alleles in murine hematopoietic progenitors typically results in AML rather than B-ALL.
To address this limitation, we developed a novel syngeneic KMT2A-r B-ALL transformation system using retroviral transduction of KMT2A-r alleles within a unique ex vivo culture platform. The resulting transformed cells transcriptionally and immunophenotypically resembled human KMT2A-r B-ALL in vitro, but surprisingly, transplantation of these cells into newborn mice rapidly produced lethal AML that retained evidence of prior B-lineage identity. We observed that higher plasma IL-7 levels in newborn recipients delayed the transition from B-ALL to AML, therefore, we pursued several strategies to enhance IL-7 signaling and stabilize B-lineage identity in vivo. Graded strengthening of IL-7 signaling through inclusion of constitutively active STAT5B or anchoring IL-7 to the B-ALL cell surface produced KMT2A-r B-ALL with progressively fewer hallmarks of myeloid identity, despite retention of the full KMT2A-fusion-dependent transcriptional program including Hoxa9, Meis1 and Runx2. Anchoring IL-7 on B-ALL blasts led to the most stable B cell identity, with all effective doses of CD19 CAR T cells eliminating B-ALL without subsequent AML relapse. In contrast, KMT2A-r B-ALL with constitutively active STAT5B partially stabilized B-lineage identity, resulting in delayed LS-AML relative to wild-type KMT2A-r B-ALL. In this latter setting, CD19 CAR T-cell treatment cleared CD19+ disease but could not prevent complete LS-AML relapse in all recipients. Finally, retroviral integration sites served as unique genetic markers for individual leukemia-initiating cells. Identical retroviral integration sites in B-ALL and AML cells from moribund animals exhibiting lineage switching showed that clones capable of producing either leukemia type accounted for over 80% of leukemic cells in neonatal recipients, indicating that bilineage potential is broadly distributed rather than restricted to rare, predetermined clones.
With this system, we showed that modulating IL‑7-STAT5 signaling produces a more human-relevant KMT2A‑r B‑ALL model. Leveraging this robust, pediatric-relevant murine model, we modulated CAR T cell dose and potency to identify factors enabling LS-AML emergence. RNA-seq revealed distinct metabolic pathway signatures in LS-AML versus de novo KMT2A-r AML. Following CAR T-cell treatment, LS-AML showed inflammatory programs consistent with adaptation to a therapy-altered microenvironment. Our model provides a tractable system to understand how CAR T-cell therapy and niche signals shape lineage plasticity, enabling strategies to anticipate and prevent lineage escape.
DISCLOSURES
Wenjuan Liao, PhD: No relevant conflicts of interest to declare.